Aquestive (AQST) CEO has 335,922 shares withheld for tax obligation

Rhea-AI Filing Summary

Aquestive Therapeutics President and CEO Daniel Barber reported a compensation-related share adjustment. On the vesting of previously granted Performance Stock Units, the company withheld 335,922 shares of common stock at $4.18 per share to cover his tax withholding obligation. After this tax-withholding disposition, Barber directly owns 668,831 common shares, and the filing shows no remaining derivative positions.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Barber Daniel

Role President and CEO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	335,922	$4.18	$1.40M

Holdings After Transaction: Common Stock — 668,831 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 335,922 shares Reference price per share: $4.18 per share Shares owned after transaction: 668,831 shares +1 more

4 metrics

Shares withheld for taxes 335,922 shares Tax-withholding disposition on PSU vesting

Reference price per share $4.18 per share Value used for tax-withholding shares

Shares owned after transaction 668,831 shares Direct common stock holdings after withholding

Tax-withholding transactions 1 transaction, 335,922 shares Form 4 transaction summary

Key Terms

Performance Stock Units, tax withholding obligation, tax-withholding disposition, Form 4

4 terms

Performance Stock Units financial

"vesting of certain Performance Stock Units ("PSUs") previously granted"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

tax withholding obligation financial

"withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation"

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barber Daniel

(Last) (First) (Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		F		335,922(1)	D	$4.18	668,831	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person.

Remarks:

	/s/ Thomas Zalewski, as Attorney-In-Fact	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Aquestive Therapeutics (AQST) report for Daniel Barber?

Aquestive Therapeutics reported that President and CEO Daniel Barber had 335,922 common shares withheld to cover taxes on vested Performance Stock Units. This was a compensation-related tax-withholding event, not an open-market stock sale, and he continues to hold 668,831 shares directly afterward.

Was the AQST CEO’s Form 4 transaction an open-market sale of shares?

No. The Form 4 shows a tax-withholding disposition, not an open-market sale. Shares were withheld by the company to satisfy Daniel Barber’s tax obligation when his Performance Stock Units vested, a common administrative step with equity compensation plans.

How many Aquestive Therapeutics shares were withheld for Daniel Barber’s taxes?

The filing reports that 335,922 shares of Aquestive Therapeutics common stock were withheld to cover Daniel Barber’s tax withholding obligation. The price referenced in the Form 4 is $4.18 per share for this compensation-related tax withholding event tied to PSU vesting.

How many AQST shares does CEO Daniel Barber own after this Form 4 event?

After the tax-withholding disposition, Daniel Barber directly owns 668,831 shares of Aquestive Therapeutics common stock. This figure reflects his holdings following the share withholding for taxes related to vesting Performance Stock Units previously granted as part of his compensation.

What triggered the tax-withholding share disposition for Aquestive’s CEO?

The disposition was triggered by the vesting of certain Performance Stock Units previously granted to Daniel Barber. When these PSUs vested, the issuer withheld shares to satisfy his tax withholding obligation, which is standard practice for equity-based executive compensation.